MCID: LVR012
MIFTS: 66

Liver Cirrhosis

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Liver Cirrhosis

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 38 12 52 42 14 69
Cirrhosis 12 29 52 41 69
Cirrhosis of Liver 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5082
ICD10 33 K74.60
MeSH 42 D008103
NCIt 47 C2951
UMLS 69 C0023890

Summaries for Liver Cirrhosis

MedlinePlus : 41 cirrhosis is scarring of the liver. scar tissue forms because of injury or long-term disease. scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. cirrhosis can lead to easy bruising or bleeding, or nosebleeds swelling of the abdomen or legs extra sensitivity to medicines high blood pressure in the vein entering the liver enlarged veins called varices in the esophagus and stomach. varices can bleed suddenly. kidney failure jaundice severe itching gallstones a small number of people with cirrhosis get liver cancer. your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. cirrhosis has many causes. in the united states, the most common causes are chronic alcoholism and hepatitis. nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. if too much scar tissue forms, you may need to consider a liver transplant. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and primary hyperoxaluria, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Liver Cirrhosis is ALB (Albumin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and NRF2 pathway. The drugs Adefovir Dipivoxil and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Liver Cirrhosis

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 355)
id Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 34.2 CYP2E1 GGT1 GPT SLC17A5 TF
2 primary hyperoxaluria 30.7 REN SERPINC1
3 obstructive jaundice 30.6 ALB EDN1 F2 SERPINC1
4 cholangiolocellular carcinoma 30.4 F2 REN
5 antiphospholipid syndrome 30.4 EDN1 REN
6 myocardial infarction 29.6 ALB EDN1 F2 HFE NPPA REN
7 hepatocellular carcinoma 29.2 AFP ALB CYP2E1 F2 GGT1 GPC3
8 primary biliary cirrhosis 11.7
9 non-hodgkin lymphoma, during pregnancy 11.1 ALB F2
10 budd-chiari syndrome 11.1
11 pulmonary arteriovenous malformation 11.1
12 lambert-eaton myasthenic syndrome 11.0 F2 TF
13 fragile x syndrome type 2 11.0 ALB F2 SERPINC1
14 htra1-related autosomal dominant cerebral small vessel disease 11.0 GPT SLC17A5
15 argyria 11.0 F2 GPT
16 atrophic vulva 11.0 ALB F2 TGFB1
17 rectum neuroendocrine neoplasm 11.0 F2 SERPINC1 TGFB1
18 pyridoxine deficiency anemia 11.0 F2 REN SERPINC1
19 lujo hemorrhagic fever 11.0 F2 NPPA SERPINC1
20 syncope 11.0 F2 SERPINC1
21 dyskeratosis congenita autosomal recessive 11.0 ALB F2 SERPINC1
22 wernicke-korsakoff syndrome 11.0 ALB REN
23 rete ovarii adenoma 11.0 ALB F2 SLC17A5
24 quinquaud's decalvans folliculitis 11.0 GPT SLC17A5
25 cutaneous fibrous histiocytoma 10.9 ALB F2 GPT
26 tonsil cancer 10.9 ALB GPT SLC17A5
27 ischemic heart disease 10.9 ALB F2 SERPINC1
28 dermatoosteolysis, kirghizian type 10.9 HFE TF
29 cataract 10.9 ALB HGF SERPINC1
30 uterine inflammatory disease 10.9 EDN1 REN
31 iga glomerulonephritis 10.9 ALB REN
32 fallopian tube leiomyosarcoma 10.9 ALB F2 GPT
33 superior limbic keratoconjunctivitis 10.9 F2 SERPINC1
34 idiopathic juvenile osteoporosis 10.9 ALB HGF NPPA
35 mediastinum leiomyoma 10.9 ALB F2 TF
36 mixed mineral dust pneumoconiosis 10.9 ALB F2 SERPINC1
37 hypodontia of incisors and premolars 10.9 NPPA REN
38 bladder sarcoma 10.9 ALB GPT TF
39 prostate neuroendocrine neoplasm 10.9 ALB REN TGFB1
40 meckel's diverticulum 10.9 ALB F2 SERPINC1
41 atrial septal defect 7, with or without av conduction defects 10.9 GGT1 NPPA REN
42 broad ligament malignant neoplasm 10.9 ALB EDN1 REN
43 lethal hydranencephaly-diaphragmatic hernia syndrome 10.9 ADH1B CYP2E1
44 chylocele of tunica vaginalis 10.9 EDN1 NPPA REN
45 follicular adenoma 10.9 F2 SERPINC1
46 joint disorders 10.9 EDN1 F2 SERPINC1
47 bernard-soulier syndrome, type a2 10.9 EDN1 F2 SERPINC1
48 hemorrhoid 10.9 ALB F2 GGT1
49 kohler's disease 10.8 ALB F2 GPT SLC17A5
50 duane retraction syndrome 10.8 AFP ALB F2

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis

Symptoms & Phenotypes for Liver Cirrhosis

UMLS symptoms related to Liver Cirrhosis:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Liver Cirrhosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 EDN1 F2 GGT1 GPC3 HFE NPPA
2 hematopoietic system MP:0005397 10.06 F2 GGT1 GPC3 HFE HGF NPPA
3 mortality/aging MP:0010768 9.8 AFP ALB CYP2E1 EDN1 F2 GGT1
4 liver/biliary system MP:0005370 9.7 AFP ALB CYP2E1 HFE HGF SERPINC1
5 renal/urinary system MP:0005367 9.23 GPC3 NPPA REN SERPINC1 TGFB1 ALB

Drugs & Therapeutics for Liver Cirrhosis

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 693)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 1,Phase 2 142340-99-6 60871
2
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2 3424-98-4 159269
3
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
4
Magnesium oxide Approved Phase 4 1309-48-4 14792
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
6
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
7
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
8
Cefoxitin Approved Phase 4 35607-66-0 441199
9
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Early Phase 1 85721-33-1 2764
10
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
11
Vancomycin Approved Phase 4 1404-90-6 441141 14969
12
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
13
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
14
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 525-66-6 4946
15
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
16
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
17
Entecavir Approved, Investigational Phase 4,Phase 1,Phase 2 142217-69-4 153941
18
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
19
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
20
Insulin Glargine Approved Phase 4 160337-95-1
21
Insulin-glulisine Approved Phase 4 207748-29-6
22
Zinc Approved Phase 4 7440-66-6 32051 23994
23
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
24
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
25
Lactulose Approved Phase 4,Phase 3,Phase 2 4618-18-2 11333
26
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 83150-76-9 383414 6400441
27
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
28
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3 14636-12-5 72081
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
30
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Tolvaptan Approved Phase 4,Phase 2,Phase 3,Phase 1 150683-30-0 216237
33
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
34
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
35
Prazosin Approved Phase 4,Phase 2 19216-56-9 4893
36
Carboplatin Approved Phase 4,Phase 2,Phase 3 41575-94-4 10339178 498142 38904
37
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
38
Ethiodized oil Approved Phase 4,Phase 3,Phase 2,Phase 1 8008-53-5
39
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 284461-73-0 216239 406563
40
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
41
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
42
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2 61825-94-3 5310940 9887054 43805 6857599
43
Bisacodyl Approved Phase 4 603-50-9
44
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128-13-2 31401
45
Midodrine Approved Phase 4,Phase 2,Phase 3 133163-28-7, 42794-76-3 4195
46
Colchicine Approved Phase 4,Phase 3,Phase 1 64-86-8 6167 2833
47
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 99210-65-8, 215647-85-1
48
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1190307-88-0 45375808
49
Norfloxacin Approved Phase 4,Phase 3,Phase 2 70458-96-7 4539
50
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078

Interventional clinical trials:

(show top 50) (show all 1646)

id Name Status NCT ID Phase Drugs
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
2 Prevention of Decompensation in Liver Cirrhosis Unknown status NCT00239096 Phase 4 losartan (drug)
3 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
4 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
5 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
6 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
7 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4 rifaximin
8 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
9 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
10 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
11 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
12 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
13 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
14 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
15 Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline Unknown status NCT00343122 Phase 4
16 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
17 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
18 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
19 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
20 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
21 Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding Unknown status NCT00966355 Phase 4 Terlipressin;Somatostatin;Octreotide
22 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
23 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
24 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
25 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
26 Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker Unknown status NCT01298271 Phase 4 propranolol
27 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
28 Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
29 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
30 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
31 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
32 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
33 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
34 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
35 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
36 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
37 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
38 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
39 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
40 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
41 Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients Unknown status NCT01853709 Phase 4 Polyethylene glycol (PEG);Bisacodyl
42 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
43 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
44 Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection Completed NCT02414880 Phase 4 Sugammadex;Neostigmine;Rocuronium
45 Enteral Nutrition in Liver Cirrhosis Completed NCT00168961 Phase 4
46 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
47 Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis Completed NCT01686698 Phase 4
48 Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation Completed NCT02249741 Phase 4 Treated with Ibandronic acid as per protocol
49 Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
50 Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver cirrhosis

Genetic Tests for Liver Cirrhosis

Genetic tests related to Liver Cirrhosis:

id Genetic test Affiliating Genes
1 Cirrhosis 29

Anatomical Context for Liver Cirrhosis

MalaCards organs/tissues related to Liver Cirrhosis:

39
Liver, Bone, Testes, Kidney, Bone Marrow, Endothelial, Spleen
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
id Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Liver Cirrhosis

Articles related to Liver Cirrhosis:

(show top 50) (show all 1598)
id Title Authors Year
1
Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein. ( 28883536 )
2017
2
Association between Serum Selenium Concentrations and Levels of Proinflammatory and Profibrotic Cytokines-Interleukin-6 and Growth Differentiation Factor-15, in Patients with Alcoholic Liver Cirrhosis. ( 28430124 )
2017
3
Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation. ( 28939443 )
2017
4
Disialo-Trisialo Bridging Phenomenon of Transferrin Isoform Detected by Capillary Electrophoresis in Patient with Alcoholic Liver Cirrhosis: First Case Report from Asia. ( 28271694 )
2017
5
Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P. ( 28903414 )
2017
6
Data on gut metagenomes of the patients with alcoholic dependence syndrome and alcoholic liver cirrhosis. ( 28138508 )
2017
7
Need to Face Liver Cirrhosis after HCV Cure with Antivirals. ( 28916156 )
2017
8
Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension. ( 28940597 )
2017
9
First description of spontaneous fungal peritonitis caused by Fusarium solani in a critically ill patient with liver cirrhosis. ( 28948024 )
2017
10
Characterization of Body Composition and Definition of Sarcopenia in Patients with Alcoholic Liver Cirrhosis: a Computed Tomography Based Study. ( 28665532 )
2017
11
Schistosomiasis and hepatopulmonary syndrome: the role of concomitant liver cirrhosis. ( 28591307 )
2017
12
A tip from the nose: rhinocerebral mucormycosis in a patient with alcoholic liver cirrhosis and cocaine abuse, an uncommon association. ( 28784893 )
2017
13
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. ( 28052155 )
2017
14
Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis. ( 28766361 )
2017
15
N-Terminal pro-B-Type Natriuretic Peptide Levels are Linked with Modified Child-Pugh Classification in Patients with Nonalcoholic Cirrhosis [NT-ProBNP and Liver Cirrhosis]. ( 27914003 )
2017
16
Current status and issues of liver transplantation for decompensated liver cirrhosis. ( 28070093 )
2017
17
Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. ( 28914957 )
2017
18
[Retropharyngeal abscess with cervical discitis and vertebral osteomyelitis caused by Escherichia coli in a patient with liver cirrhosis]. ( 28603238 )
2017
19
A Comprehensive Review of Bioelectrical Impedance Analysis and Other Methods in the Assessment of Nutritional Status in Patients with Liver Cirrhosis. ( 28894465 )
2017
20
Anti-fibrotic Effects of Synthetic Oligodeoxynucleotide for TGF-I^1 and Smad in an Animal Model of Liver Cirrhosis. ( 28918026 )
2017
21
MiRNA-target network analysis identifies potential biomarkers for Traditional Chinese Medicine (TCM) syndrome development evaluation in hepatitis B caused liver cirrhosis. ( 28887510 )
2017
22
Estrogen receptor I^ selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells. ( 28884481 )
2017
23
Bacterial meningitis complicating the course of liver cirrhosis. ( 28616745 )
2017
24
Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. ( 28936406 )
2017
25
Impact of genetic variation in the vasopressin 1a receptor on the development of organ failure in patients admitted for acute decompensation of liver cirrhosis. ( 28079670 )
2017
26
Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. ( 28070704 )
2017
27
Cost of illness of non-alcoholic liver cirrhosis in Japan: A time trend analysis and future projections. ( 28497644 )
2017
28
Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma. ( 28824076 )
2017
29
Liver cirrhosis caused by chronic Budd-Chiari syndrome. ( 28834866 )
2017
30
Bacteremia Caused by Campylobacter Fetus in a Patient With Hepatitis B Virus Infection Complicated with Alcoholic Liver Cirrhosis. ( 28879715 )
2017
31
Effect of Yi Guan Jian decoction on differentiation of bone marrow mesenchymalstem cells into hepatocyte-like cells in dimethylnitrosamine-induced liver cirrhosis in mice. ( 28035356 )
2017
32
Response to hepatitis B vaccination in patients with liver cirrhosis. ( 28905444 )
2017
33
Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection. ( 28948181 )
2017
34
Hepatic adenomatosis in liver cirrhosis. ( 28932768 )
2017
35
Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis. ( 28895774 )
2017
36
Study of the sleep quality and psychological state of patients with hepatitis B liver cirrhosis. ( 28888081 )
2017
37
Up to date of therapeutic approach for liver cirrhosis. ( 28070098 )
2017
38
Acoustic radiation force impulse elastography: comparison and combination with other noninvasive tests for the diagnosis of compensated liver cirrhosis. ( 28067683 )
2017
39
Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis. ( 28904387 )
2017
40
Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liverA disease. ( 28947134 )
2017
41
Deregulation of miR-34a and Its Chaperon Hsp70 in Hepatitis C virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma Patients ( 28950684 )
2017
42
A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men. ( 27992614 )
2016
43
Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis. ( 27802312 )
2016
44
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. ( 26803356 )
2016
45
Does pressure cause liver cirrhosis? The sinusoidal pressure hypothesis. ( 28082801 )
2016
46
Behavior of Oxidative Stress Markers in Alcoholic Liver Cirrhosis Patients. ( 28074118 )
2016
47
Role of Chymase in the Development of Liver Cirrhosis and Its Complications: Experimental and Human Data. ( 27637026 )
2016
48
IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS/p38 signal pathway. ( 26742425 )
2016
49
Letter to the editor: treatment for superficial esophageal cancer with rectal varices bleeding in a patient with alcoholic liver cirrhosis. ( 26728025 )
2016
50
Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. ( 27034286 )
2016

Variations for Liver Cirrhosis

Copy number variations for Liver Cirrhosis from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis

Expression for Liver Cirrhosis

Search GEO for disease gene expression data for Liver Cirrhosis.

Pathways for Liver Cirrhosis

GO Terms for Liver Cirrhosis

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 AFP ALB EDN1 F2 GPC3 HGF
2 blood microparticle GO:0072562 9.77 ALB F2 SERPINC1 TF TGFB1
3 endoplasmic reticulum lumen GO:0005788 9.7 AFP ALB F2 GPC3 SERPINA1 SERPINC1
4 platelet alpha granule lumen GO:0031093 9.62 ALB HGF SERPINA1 TGFB1
5 extracellular space GO:0005615 9.55 AFP ALB EDN1 F2 GGT1 GPC3
6 basal part of cell GO:0045178 9.43 EDN1 HFE TF
7 HFE-transferrin receptor complex GO:1990712 9.4 HFE TF

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.76 F2 IFNA1 SERPINA1 SERPINC1
2 female pregnancy GO:0007565 9.67 HFE NPPA TGFB1
3 regulation of blood pressure GO:0008217 9.65 EDN1 NPPA REN
4 post-translational protein modification GO:0043687 9.63 AFP ALB GPC3 SERPINA1 SERPINC1 TF
5 hemostasis GO:0007599 9.58 F2 SERPINA1 SERPINC1
6 cellular response to iron ion GO:0071281 9.43 HFE TF
7 acute-phase response GO:0006953 9.43 F2 HFE SERPINA1
8 response to ozone GO:0010193 9.37 CYP2E1 EDN1
9 platelet degranulation GO:0002576 9.35 ALB HGF SERPINA1 TF TGFB1
10 positive regulation of odontogenesis GO:0042482 9.32 EDN1 TGFB1
11 cellular protein metabolic process GO:0044267 9.23 AFP ALB F2 GPC3 NPPA SERPINA1

Molecular functions related to Liver Cirrhosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 EDN1 IFNA1 TGFB1 THPO
2 receptor binding GO:0005102 9.35 EDN1 F2 HFE NPPA REN
3 transferrin receptor binding GO:1990459 9.16 HFE TF
4 growth factor activity GO:0008083 8.92 F2 HGF TGFB1 THPO

Sources for Liver Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....